bioRxiv Science⌕ Search

Biology subjects

Wicks, A.

Publications and source records attributed to Wicks, A..

2 recordsLinked to original sources

Towards Useful and Private Synthetic Omics: Community Benchmarking of Generative Models for Transcriptomics Data

BackgroundThe synthesis of anonymized data derived from real-world cohorts offers a promising strategy for regulatory-compliant and privacy-preserving biological data sharing, potentially facilitating model development that can improve predictive performance. However, the extent to which generative models can preserve biological signals while remaining resilient to adversarial privacy attacks in high-dimensional omics contexts remains underexplored. To address this gap, the CAMDA 2025 Health Privacy Challenge launched a community-driven effort to systematically benchmark synthetic and privacy-preserving data generation for bulk RNA-seq cohorts. ResultsBuilding on this initiative, we systematically benchmarked 11 generative methods across two cancer cohorts ([~]1,000 and [~]5,000 patients) over 978 landmark genes. Methods were evaluated across complementary axes of distributional fidelity, downstream utility, biological plausibility and empirical privacy risk, with emphasis on trade-offs between vulnerability to membership inference attacks (MIA) and other evaluation dimensions. Expressive deep generative models achieved strong predictive utility and differential expression recovery, but were often more vulnerable to membership inference risk. Differentially private methods improved resistance to attacks at the cost of reduced utility, while simpler statistical approaches offered competitive utility with moderate privacy risk and fast training. ConclusionsSynthetic bulk RNA-seq quality is inherently multi-dimensional and shaped by trade-offs between utility, biological preservation and privacy. Our results indicate that differences in model architecture drive distinct trade-offs across these axes, suggesting that model choice should align with dataset characteristics, intended downstream use and privacy requirements. Privacy risk should also be assessed using multiple complementary attack methods and, where possible, formal differential privacy protection.

bioinformatics↗

The ubiquitin-dependent ATPase p97 removes cytotoxic trapped PARP1 from chromatin

Summary paragraphPoly-(ADP-ribose) polymerase inhibitors (PARPi) elicit anti-tumour activity in homologous recombination defective cancers by promoting cytotoxic, chromatin-bound, "trapped" PARP1. How cells process trapped PARP1 remains unclear. By exploiting wild-type or trapping-resistant PARP1 transgenes combined with either a rapid immunoprecipitation mass-spectrometry of endogenous proteins (RIME)-based approach, or PARP1 Apex2-proximity labelling linked to mass-spectrometry, we generated proteomic profiles of trapped and non-trapped PARP1 complexes. This combined approach identified an interaction between trapped PARP1 and the ubiquitin-regulated p97 ATPase (aka VCP). Subsequent experiments demonstrated that upon trapping, PARP1 is SUMOylated by the SUMO-ligase PIAS4 and subsequently ubiquitinated by the SUMO-targeted E3-ubiquitin ligase, RNF4, events that promote p97 recruitment and p97 ATPase-mediated removal of trapped-PARP1 from chromatin. Consistent with this, small molecule p97 complex inhibitors, including a metabolite of the clinically-used drug disulfiram (CuET) that acts as a p97 sequestration agent, prolong PARP1 trapping and thus enhance PARPi-induced cytotoxicity in homologous recombination-defective tumour cells and patient-derived tumour organoids. Taken together, these results suggest that p97 ATPase plays a key role in the processing of trapped PARP1 from chromatin and the response of homologous recombination defective tumour cells to PARPi.

molecular biology↗